The mental health of adolescents and pre-adolescents living with inherited arrhythmia syndromes: a systematic review of the literature

Abstract

Potentially fatal arrhythmias add to the mental health challenges of adolescence. This systematic review sought to summarise current knowledge regarding the mental health of adolescents and pre-adolescents diagnosed with inherited arrhythmia syndromes. Searches combining psychological problems with inherited cardiac arrhythmia diagnoses identified 16 studies with paediatric (<18 years) inherited arrhythmia patients. All studies were cross-sectional; 8/16 required an implantable cardioverter defibrillator. Methods were quantitative (n=11), qualitative (n=4), or mixed (n=1), with 14-100% of participants having an inherited arrhythmia syndrome. Mean/median age in 13/16 studies was 12-16 years. Patients and parents reported lower quality of life, particularly in relation to physical function, social relationships, restriction of peer activities, bodily pain, and mental and emotional health. Self-perceptions and behaviour were similar to healthy populations. Rates of anxiety and depression (15-33% of these patients) were not increased in these studies where patients were assessed 2+ years after diagnosis. Higher mental health risk occurred among patients who have a diagnosed sibling, those with cardiomyopathy, and those who report decreased quality of life. Mental health research among youth with inherited arrhythmias is extremely limited and of low quality. Data, primarily from patients 2-4 years after diagnosis or treatment with an implantable cardioverter defibrillator, indicate that quality of life may be decreased and 15-33% experience mental health issues. Future research is required to examine the mental health and quality of life of paediatric patients with inherited arrhythmia syndromes, whether or not they have an implantable cardioverter defibrillator, from time of diagnosis.

Ethical problems of genetic testing for hereditary cardiovascular diseases

“…Так, в обзоре 16 исследований с участием детей (<18 лет) с наследственными аритмиями показано, что пациенты и родители сообщили о более низком качестве жизни, особенно в отношении физических функций, социальных отношений, ограничения взаимодействий со сверстниками, психического и эмоционального здоровья. У 15-33% пациентов возникают проблемы с психическим здоровьем, причем более высокий риск таких нарушений был у пациентов, имеющих больных брата или сестру, пациентов с кардиомиопатией и у сообщивших о снижении качества жизни [42]. Аналогичные данные приводят и другие авторы [43].…”

Cardiac rehabilitation for children and young people (CardioActive): protocol for a single-blind randomised feasibility and acceptability study of a centre-based cardiac rehabilitation programme versus usual care in 11–16 years with heart conditions

“…Survivors of CHD face challenges and comorbidities which impact their ability to function,2 future employment and progression into independent adulthood 3 4. CYP with heart conditions have a reduced quality of life and poorer psychological functioning,5–7 as 41% of CYP with CHD experience significant difficulties adjusting to their heart condition, and 30% experience clinically significant anxiety or depression 7–13. In addition, overprotection from parents, educators and healthcare staff contributes to reduced physical activity and exercise intolerance 14–17.…”

Dynamic Electrocardiogram under P Wave Detection Algorithm Combined with Low-Dose Betaloc in Diagnosis and Treatment of Patients with Arrhythmia after Hepatocarcinoma Resection

“…At present, β-blocker drugs are gradually widely used in arrhythmia, especially in patients with primary liver cancer after hepatectomy, such as β-blocker metoprolol succinate sustained-release tablets (Betaloc) [21,22]. However, because β-blockers have a certain blocking effect on β-receptors, there are certain limitations in clinical application [23,24]. In addition, there is still a lack of relevant studies on the effect of dosage of β-blocker metoprolol succinate sustained-release tablets (Betaloc) on arrhythmia and its therapeutic effect [25,26].…”